Labiotech

Labiotech.eu is the top online platform focused on the European Biotechnology sector.

Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#251695

United States

#139951

Health/Health Conditions and Concerns

#325

Traffic sources

Monthly visitors

Articles

Pharma giants pull back on AAV gene therapy: What’s the next big move?

3 days ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Once hailed as the solution to delivering gene therapies, adeno-associated virus (AAV) vectors have seen their star dim in recent years.
Unlocking immunity: the power of TLR agonists

1 week ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. In the vast field of immunotherapy, toll-like receptor agonists (TLR) emerged as powerful catalysts to boost the immune system.
Top biotech deals of April 2025

1 week ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Biotech deals are known to . In the month of April 2025, a number of pharma giants took part in mergers and acquisitions (M&As) as well as licensing deals. Some of these included Lilly, Merck, and Boehringer Ingelheim.
What happened to COVID vaccine companies?

1 week ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility.
What's in store for the NSCLC therapeutic space?

2 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. For decades, non-small cell lung cancer (NSCLC) stood as one of the formidable challenges in oncology, often diagnosed late and treated with limited options. But now, it looks like the therapeutic field is changing.
Innovation in crisis: federal budget cuts threaten future of U.S. research

2 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. As the world flocks towards medical research and innovation, the U.S. is hitting the brakes. Sweeping cuts across federal research programs are threatening to stall scientific progress and could dim the country’s edge.
The past, present, and future of genome sequencing

2 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Genome sequencing is the process of determining the complete DNA sequence of an organism’s genome, a step-by-step decoding of all the genetic instructions.
Tariffs and trade war: A guide for expanding biotech business internationally

3 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
Tariffs and trade war: A guide for expanding biotech business internationally

3 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
Seven biotech companies to watch in the hepatitis B space in 2025

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Hepatitis B is a serious liver infection that is caused by the hepatitis B virus (HBV).